On Friday, Bristol Myers Squibb announced its agreement to acquire the biopharmaceutical company Karuna Therapeutics for $14 billion in cash, equivalent to $330 per share.
Subsequent to this announcement, Karuna Therapeutics witnessed a remarkable upsurge in its stock, soaring by more than 47%, and concluding at a value of $317.85 per share.
Concurrently, Bristol Myers Squibb observed a moderate 2% increase in its shares.
This discerning acquisition holds paramount significance for Bristol Myers Squibb, strategically positioning itself to fortify its pharmaceutical pipeline.
This strategic move is particularly salient in light of the diminished demand for its blood cancer drug, Revlimid, during the third quarter.
The decreased demand can be attributed to heightened competition from a generic alternative.
The unanimous approval from the boards of directors at both Bristol Myers and Karuna underscores the meticulous consideration and alignment of interests in this acquisition.
As stipulated in the official release, the transaction is projected to conclude in the first half of 2024, marking a pivotal milestone in the strategic evolution of both entities.
Read Also: The Alarming Challenge of Treatment Approval Delays for Cancer Patients
Karuna’s Key Asset, KarXT, Set to Address Schizophrenia in Late 2024
Karuna specializes in developing medications for individuals with neurological and psychiatric conditions.
Its primary asset, the antipsychotic KarXT, is projected to become a treatment option for adults with schizophrenia starting in late 2024, as outlined in the release.
Bristol Myers Squibb CEO Christopher Boerner, in a formal statement, highlighted the substantial opportunities in neuroscience.
He emphasized that the addition of Karuna to their portfolio enhances their position, facilitating the swift expansion and diversification of offerings in the neuroscience field.
Boerner anticipates that KarXT will be a contributing factor to the company’s growth trajectory from the late 2020s into the following decade.
The release further indicates that KarXT is undergoing evaluation as a potential therapeutic option for Alzheimer’s disease psychosis and a specific type of bipolar disorder.
Karuna CEO Bill Meury emphasized that the company’s portfolio represents advancements in treatment that have not been witnessed in many years.
Read Also: Missing Your ANCHOR Rebate? Here’s Your Step-by-Step Guide on What to Do Next
